L74 Stock Overview
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
WuXi XDC Cayman Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.14 |
| 52 Week High | HK$5.50 |
| 52 Week Low | HK$1.58 |
| Beta | 0 |
| 1 Month Change | 11.29% |
| 3 Month Change | 13.11% |
| 1 Year Change | 93.46% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 32.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| L74 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -4.2% | -2.0% | 0.9% |
| 1Y | 93.5% | -5.8% | 13.2% |
Return vs Industry: L74 exceeded the German Life Sciences industry which returned -5.8% over the past year.
Return vs Market: L74 exceeded the German Market which returned 13.2% over the past year.
Price Volatility
| L74 volatility | |
|---|---|
| L74 Average Weekly Movement | 13.1% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: L74's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: L74's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 2,041 | Jimmy Li | wuxixdc.com |
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. The company engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It provides international sales contracting, biologics discovery, development, and manufacturing services.
WuXi XDC Cayman Inc. Fundamentals Summary
| L74 fundamental statistics | |
|---|---|
| Market cap | €5.10b |
| Earnings (TTM) | €131.33m |
| Revenue (TTM) | €497.57m |
38.8x
P/E Ratio10.2x
P/S RatioIs L74 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L74 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.05b |
| Cost of Revenue | CN¥2.81b |
| Gross Profit | CN¥1.24b |
| Other Expenses | CN¥170.22m |
| Earnings | CN¥1.07b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.89 |
| Gross Margin | 30.60% |
| Net Profit Margin | 26.40% |
| Debt/Equity Ratio | 7.2% |
How did L74 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 19:39 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WuXi XDC Cayman Inc. is covered by 24 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |
| Bo Yu | China International Capital Corporation Limited |